[* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed]
[* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed]
[SINOVAC BIOTECH LTD. 10,000,000 Common Shares ($ 0.001 par value per Share) UNDERWRITING AGREEMENT January 27, 2010 UNDERWRITING AGREEMENT January 27, 2010 UBS Securities LLC c/o UBS Securities LLC 299 Park Avenue New York, New York 10171-0026 Piper Jaffray & Co. c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 as Managing Underwriters and Representatives] [1 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o Incorporation by Reference 333-163165). 2 SINOVAC BIOTECH LTD.]
[SINOVAC BIOTECH LTD. 10,000,000 Common Shares ($ 0.001 par value per Share) UNDERWRITING AGREEMENT January 27, 2010 UNDERWRITING AGREEMENT January 27, 2010 UBS Securities LLC c/o UBS Securities LLC 299 Park Avenue New York, New York 10171-0026 Piper Jaffray & Co. c/o Piper Jaffray & Co. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 as Managing Underwriters and Representatives] [1 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o Incorporation by Reference 333-163165). 2 SINOVAC BIOTECH LTD.]
[Sinovac Biotech Ltd. 10,000,000 Common Shares We are offering 10,000,000 common shares through this prospectus supplement and the accompanying prospectus. Our common shares are listed on the NASDAQ Global Market under the symbol "SVA." The last reported sale price of our common shares on January 27, 2010 was $6.11 per share. Investing in our common shares involves a high degree]
[Sinovac Biotech Ltd. 10,000,000 Common Shares We are offering 10,000,000 common shares through this prospectus supplement and the accompanying prospectus. Our common shares are listed on the NASDAQ Global Market under the symbol "SVA." The last reported sale price of our common shares on January 27, 2010 was $6.11 per share. Investing in our common shares involves a high degree]
[Law Debenture Corporate Services Inc. 400 Madison Avenue, 4th Floor New York, New York 10017 212-750-6474 (Name, address and telephone number of agent for service) Copies to: David T. Zhang, Esq. Eugene Y. Lee, Esq. Latham & Watkins 41 st Floor, One Exchange Square 8 Connaught Place, Central] [[Letterhead of Rhudd & Associates] January 27, 2010 Sinovac Biotech Ltd. No.39 Shangdi Xi Road, Haidian District, Beijing 100085 Peoples Republic of China Dear Sirs, Sinovac Biotech Ltd. (the Company) For the purposes of giving this opinion, we have examined and relied upon copies of the following documents: (i) the 462(b) Registration Statement; and (ii) the Shelf Registration Statement. We] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM in the Registration Statement (Form F-3) filed with on January 27, 2010 and related Prospectus of for the registration of 1,500,000 common shares and to the incorporation by reference therein of We consent to the reference to our firm under the caption Experts Vancouver, Canada January 27, 2010 Chartered Accountants]
[Law Debenture Corporate Services Inc. 400 Madison Avenue, 4th Floor New York, New York 10017 212-750-6474 (Name, address and telephone number of agent for service) Copies to: David T. Zhang, Esq. Eugene Y. Lee, Esq. Latham & Watkins 41 st Floor, One Exchange Square 8 Connaught Place, Central] [[Letterhead of Rhudd & Associates] January 27, 2010 Sinovac Biotech Ltd. No.39 Shangdi Xi Road, Haidian District, Beijing 100085 Peoples Republic of China Dear Sirs, Sinovac Biotech Ltd. (the Company) For the purposes of giving this opinion, we have examined and relied upon copies of the following documents: (i) the 462(b) Registration Statement; and (ii) the Shelf Registration Statement. We] [CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM in the Registration Statement (Form F-3) filed with on January 27, 2010 and related Prospectus of for the registration of 1,500,000 common shares and to the incorporation by reference therein of We consent to the reference to our firm under the caption Experts Vancouver, Canada January 27, 2010 Chartered Accountants]
[Sinovac Biotech Ltd. 8,650,000 Common Shares We are offering 8,650,000 common shares through this prospectus supplement and the accompanying prospectus. Our common shares are listed on the NASDAQ Global Market under the symbol "SVA." The last reported sale price of our common shares on January 19, 2010 was $7.49 per share. Investing in our common shares involves a high degree]
[Equity Joint Venture Contract for the establishment of Sinovac (Dalian) Vaccine Technology Co., Ltd. i Table of Contents Chapter I The Parties 1 Chapter II Establishment of Joint Venture 1 Chapter III Purpose, Business Scope and Size 2 Chapter IV Aggregate Investment and Registered Capital 2 Chapter V Contribution Proportion and Deadline of the Parties 2 Chapter VI Responsibilities of] [MEMORANDUM This Memorandum is made on 22 November 2009: BETWEEN: 1. Dalian Jingang Group Co., Ltd. , with its legal address at No. 59, Liaohe Middle Road, Dalian 2. Sinovac Biotech (Hong Kong) Ltd. , a limited liability company duly incorporated and validly existing under the laws of the Hong Kong Special Administrative Region, the Peoples Republic of China (hereinafter] [EQUITY INTEREST TRANSFER AGREEMENT BY AND BETWEEN DALIAN JINGANG GROUP CO., LTD. AND SINOVAC (HONG KONG) BIOTECH LTD. IN RESPECT OF 25% EQUITY INTEREST OF December 17, 2009 This Agreement is made on BETWEEN: 1. Dalian Jingang Group Co., Ltd., a limited liability company organized and existing under the laws of the Peoples Republic of China (hereinafter referred to as] [Sinovac Announces Recent Developments BEIJING, January 20, 2010 Sinovac Biotech Ltd. (NASDAQ: SVA) (Sinovac or the Company), a leading China-based vaccine manufacturer, today announced the following recent developments. Dalian Joint Venture Acquisition of Buildings and Land Sinovac is in advanced negotiations for the acquisition of buildings, land use rights and utility facilities for a total consideration of approximately RMB120] [01 - 32371 SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, Peoples Republic of China Form 20-F x Form 40-F o o o Incorporation by Reference 2]
